Fludarabine
Cirrhosis
National Center for Global Health and Medicine, JapanSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
69 Active assets in the Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) General Hospital of Shenyang Military Region | Phase 4 | BBB |
Tolvaptan Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Ribavirin Peking University People's Hospital | Phase 4 | BBB |
NORMAL HUMAN SERUM ALBUMIN King George's Medical University | Phase 4 | BBB |
OMBITASVIR AbbVie | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →